TG Therapeutics, Inc. Aktie News

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in San Diego, California. Links to each presentation are included below.

Hussman Stratgic Advisors sold 126,000 shares of TG Therapeutics. The fund no longer holds any shares.

The companies are projected to grow sales rapidly through 2027, and many of the stocks are expected to show double-digit increases this year.

TG Therapeutics (TGTX) is upgraded from Hold to Strong Buy as BRIUMVI demonstrates accelerating revenue growth and market share gains in the MS market. TGTX guides for 2026 BRIUMVI U.S. net revenue of $825–$850 million, implying ~40% YoY growth and continued base expansion beyond Q4 2025 run rate. Strategic low pricing, administrative simplification, and subcutaneous formulation development und...

TG Therapeutics, Inc. (TGTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will present at the 44th Annual J.P.

TG Therapeutics, Inc. is my favorite in the multiple sclerosis therapeutics market. In my opinion, it's Briumvi that has the best efficacy among anti-CD20 monoclonal antibodies, including Ocrevus and Kesimpta. Thanks to the increased demand for Briumvi, TG Therapeutics' EBIT margin increased by 3% year-on-year to 18.2%.

NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the 8th Annual Evercore Healthcare Conference, which is taking place from December 2 - 4, 2025.